Press Releases EQL Pharma AB

Equities

EQL

SE0005497732

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
43.5 ^SEK	+0.46%		+1.87%	+30.24%

Apr. 22	EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	CI
Feb. 13	EQL Pharma AB Provides Sales Guidance for the Year 2023/24	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24	Apr. 29	AQ
Mellozzan[® ](melatonin) launched in Germany and Austria	Apr. 22	AQ
Mellozzan[® ](melatonin) have gained marketing approval in the UK	Mar. 14	AQ
Nomination committee for the 2024 Annual General Meeting	Feb. 16	AQ
EQL Pharma: Q3 numbers supportive of inflection point	Feb. 14	AQ
Interim Report April - December 2023	Feb. 13	AQ
Invitation to presentation in connection with EQL Pharma's quarterly report, third quarter, 2023/24	Jan. 30	AQ
EQL Pharma: Growth and margin inflection point – Q3(23/24) preview	Jan. 24	AQ
EQL Pharma: A repeat prescription for growth	Nov. 23	AQ
EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles	Nov. 20	AQ
Interim Report April - September 2023	Nov. 17	AQ
Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24	Nov. 06	AQ
Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria	23-10-06	AQ
EQL Pharma : Annual report 2022/2023	23-08-25	PU
Bulletin from the annual general meeting in EQL Pharma AB on 17 August 2023	23-08-17	AQ
Interim Report April - June 2023	23-08-16	AQ
Mellozzan[®] (melatonin) is launched in Denmark and Norway by EQL Pharma's license partner Medice Arzneimittel Pütter GmbH & Co. KG	23-08-15	AQ
Invitation to presentation in connection with EQL Pharma's quarterly report, first quarter, 2023/24	23-07-31	AQ
EQL Pharma : The Nomination Committee’s proposals and reasoned statement	23-07-06	PU
EQL Pharma : Resolution on implementation of a long-term incentive program	23-07-06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EQL Pharma AB

Equities

EQL

SE0005497732

Press Releases

Filters